Navigation Links
EpiCept Announces Successful Completion of Enrollment for Phase I Trial of EPC2407
Date:10/7/2007

e will not receive any significant payments under our agreement with Myriad, the risk that the development of our other apoptosis product candidates will not be successful, the risk that our ASAP technology will not yield any successful product candidates, the risk that clinical trials for NP-1 will not be successful, that NP-1 will not receive regulatory approval or achieve significant commercial success, the risk that our other product candidates that appeared promising in early research and clinical trials do not demonstrate safety and/or efficacy in larger-scale or later stage clinical trials, the risk that EpiCept will not obtain approval to market any of its product candidates, the risks associated with reliance on additional outside financing to meet its capital requirements, the risks associated with dependence upon key personnel, the risks associated with reliance on collaborative partners and others for further clinical trials, development, manufacturing and commercialization of our product candidates; the cost, delays and uncertainties associated with our scientific research, product development, clinical trials and regulatory approval process; our history of operating losses since our inception; competition; litigation; risks associated with prior material weaknesses in our internal controls; and risks associated with our ability to protect our intellectual property. These factors and other material risks are more fully discussed in EpiCept's periodic reports, including its reports on Forms 8-K, 10-Q and 10-K and other filings with the U.S. Securities and Exchange Commission. You are urged to carefully review and consider the disclosures found in EpiCept's filings which are available at http://www.sec.gov or at http://www.epicept.com. You are cautioned not to place undue reliance on any forward-looking statements, any of which could turn out to be wrong due
'/>"/>
SOURCE EpiCept Corporation
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. EpiCept Corporation to Present New NP-1 Data at American Pain Society Meeting
2. Mode of Action of EpiCept-Licensed Cancer Compound Profiled at AACR
3. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
4. Sygnis Pharma AG announces date for presentation of clinical results
5. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
6. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
7. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
8. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
9. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
10. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
11. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/2/2015)... , June 2, 2015  Only a quarter of ... managing the patients they prescribe them to, according to ... School of Medicine (BUSM) and myCME , ... Daniel Alford, M.D. , director of BUSM,s ... program , said, "This indicates a critical need for ...
(Date:6/2/2015)... -- ErgoNurse, the leader in bedside safety management solutions, and Briggs ... the United States , have formalized a partnership to ... nursing markets. ... Thousands of healthcare professionals in acute ... the ErgoNurse products to stop unnecessarily utilizing their backs for ...
(Date:6/2/2015)... -- CytRx Corporation (NASDAQ: CYTR ), a biopharmaceutical research ... it has reached an agreement to settle the stockholder ... Court of Chancery, which names as defendants a ... officers, and names the Company as a nominal defendant. ... Corp. Stockholder Derivative Litigation , C.A. No. 9864-VCL, relates ...
Breaking Medicine Technology:Survey Results Show Few Doctors Are Very Confident Managing Patients on Opioids 2ErgoNurse and Briggs Healthcare Positioned to Completely Eliminate the Unnecessary Cost of Healthcare-Related Back Injuries 2CytRx Announces Settlement of Stockholder Derivative Lawsuit in Delaware 2CytRx Announces Settlement of Stockholder Derivative Lawsuit in Delaware 3CytRx Announces Settlement of Stockholder Derivative Lawsuit in Delaware 4
... 31, 2011 NewCardio, Inc., (OTC Bulletin Board: ... today that the Company has been invited to present ... at an upcoming conference entitled "Cardiovascular Safety in Drug ... Drug Administration (FDA), the Cardiac Safety Research Consortium (CSRC) ...
... March 31, 2011 The Breast Journal ... of image-guided needle biopsy of suspicious breast cancer lesions ... the Naviscan high-resolution breast PET scanner, otherwise known as ... alone has been able to target regions in the ...
Cached Medicine Technology:NewCardio Invited to Present Latest QTinno Performance Improvements at FDA-Sponsored Conference on Cardiovascular Safety in Drug Development 2NewCardio Invited to Present Latest QTinno Performance Improvements at FDA-Sponsored Conference on Cardiovascular Safety in Drug Development 3NewCardio Invited to Present Latest QTinno Performance Improvements at FDA-Sponsored Conference on Cardiovascular Safety in Drug Development 4NewCardio Invited to Present Latest QTinno Performance Improvements at FDA-Sponsored Conference on Cardiovascular Safety in Drug Development 5NewCardio Invited to Present Latest QTinno Performance Improvements at FDA-Sponsored Conference on Cardiovascular Safety in Drug Development 6Research on Crucial Role of PET-Guided Biopsy in Initial Breast Cancer Diagnosis and Presurgical Planning Published in The Breast Journal 2
(Date:6/2/2015)... Detroit, MI (PRWEB) June 02, 2015 ... called “Fighting Addiction Together” in the Hall of Legends ... wide receiver and motivational speaker Herman Moore, the goal ... state of addiction in today’s society, highlight the benefits ... to inform the attendees about the options that are ...
(Date:6/2/2015)... (PRWEB) June 02, 2015 Residents looking ... quality care in a more convenient location now that ... Partin Village Plaza, 2310 E. Irlo Bronson Memorial Highway, ... located less than a mile away from its original ... décor, more spacious patient areas with digital intraoral and ...
(Date:6/2/2015)... UCLA Health and Exer have completed negotiations and ... urgent care services in Los Angeles County. The ... California Board of Regents and the Exer Board of ... purchase a minority share of four existing Exer urgent ... Northridge and creates opportunity to grow and develop new, ...
(Date:6/2/2015)... June 02, 2015 The nation’s ... lawsuit ( http://www.consumerinjurylawyers.com/wright-profemur-hip-replacement ) is now underway in ... court documents, opening statements were presented on May ... etchings on the Profemur hip replacement made the ... to snap just three years after it had ...
(Date:6/2/2015)... Radaris ” was featured on NewsWatch as part of its ... coolest applications on the market for iOS, Android, and Windows. ... the app review and shared with viewers can help users ... According to Psychology Today, humans are a curious species by ... is a part of human development. People are using the ...
Breaking Medicine News(10 mins):Health News:Rehabilitation Facility Graduate Shares Her Story at "Fighting Addiction Together" Conference 2Health News:Coast Dental Office Opening In Kissimmee with Expanded Technology 2Health News:UCLA Health Partners With Exer - More Than Urgent Care 2Health News:First of More Than 1,200 Wright Hip Lawsuits Goes to Trial in California Superior Court 2Health News:First of More Than 1,200 Wright Hip Lawsuits Goes to Trial in California Superior Court 3Health News:A Comprehensive People Search Application Was Featured on NewsWatch Television 2
... , Girling Health Care to utilize Santrax Time and ... , PORT WASHINGTON, N.Y. and AUSTIN, Texas, June ... of information technology solutions to the home healthcare and ... Healthcare company, announced an agreement by which Girling will ...
... Va., June 23 According to a new report from ... screened by doctors for depression. The group said that all ... show potential risk for depression and suicidal tendencies. While there ... of kids, the mental and emotional health of children does ...
... "Deinstallation" Seen Among Physician Groups in Phoenix ... , NASHVILLE, Tenn., June ... intelligence, reports that while health systems and physician groups in ... in adopting electronic medical records (EMR), there is a high ...
... Region recognizes ... ... Medical Center and CHRISTUS St. Vincent Medical Group in Santa Fe, New Mexico, through teamwork, ... in nine months. CHRISTUS Health began managing CHRISTUS St. Vincent in April 2008 ...
... is Nordic Naturals newest product for children, the "ultimate fish ... natural tangerine flavor. Perfect for two-year-olds and up, Nordic Omega-3 ... from anchovies and sardines, two sustainable sources of high quality ... mg of fish oil and offers 136 mg of omega-3. ...
... ... Work Harder for Them to Achieve Better ROI , ... Scottsdale, Ariz. (PRWEB) June 23, 2009 -- In ... leaving enterprises vulnerable to threats. According to the Ponemon Institute, 2008 Cost of a ...
Cached Medicine News:Health News:Harden Healthcare Expands Relationship with Sandata Technologies 2Health News:Should All Kids Be Screened for Depression? This Expert Says Yes and Explains How It Can Save Lives 2Health News:Electronic Medical Record Technology Uptake Faces Challenges 2Health News:CHRISTUS Health New Mexico Region Focuses on Cost Management; Saves $1.8 Million 2Health News:CHRISTUS Health New Mexico Region Focuses on Cost Management; Saves $1.8 Million 3Health News:Nordic Omega-3 Fishies from Nordic Naturals Offers Quality EPA and DHA for Children with 'Kid Pleasin' Taste 2Health News:Lumension Audiocast With Aberdeen Group Highlights How to Reduce IT Costs By Effectively Managing and Securing Endpoints 2Health News:Lumension Audiocast With Aberdeen Group Highlights How to Reduce IT Costs By Effectively Managing and Securing Endpoints 3
ThermoPrep 3's two systems in "one" approach, its capability to accommodate up to two standard microplates and its user-selectable settings offers the versatility and throughput you need in today's l...
... four-color, automated benchtop flow cytometry system that ... Designed specifically to support a wide range ... instrument control, auto-sample loading, and push-button fluidic ... is fully modular so it can be ...
... cytometer especially suited for cell analysis ... CyFlow allows to analyze scatter signals ... fluorescence channels. Data acquisition, analysis, and ... built-in PC employing Partec DPAC software, ...
This unique system combines the analytical power of a research cytometer into a compact, truly walk away, clinical analyzer ergonomically designed to expedite sample throughput....
Medicine Products: